ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TRVI vs TRAX // 10Y YIELD & FRED MACRO BETA

Trevi Therapeutics Inc. (NASDAQ) VS. First Tracks Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TRVI 4 — TRAX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRVI VS. TRAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TRVI TRAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -23.70% -35.00% +11.30 TRVI /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.14% -7.53% +5.39 TRVI /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 TRVI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.4 65.5 -15.10 TRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.93B $1.89B $37.8M TRVI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TRVI REV TRAX REV TRVI GROSS % TRAX GROSS % TRVI FCF TRAX FCF
FY 2025 $138.1M $501.2M — — -$42.1M -$143.0M
FY 2024 $144.3M $507.1M — — -$38.3M -$126.2M
FY 2023 $95.0M — — — -$31.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRVI // BETA —
TRAX // BETA —